High-density lipoprotein (HDL) has become known as “good cholesterol” because it helps reduce risk of stroke and heart attack. However, new research found that both high and low levels of HDL could increase a person’s risk of premature death.
High-density lipoprotein (HDL) has become known as “good cholesterol” because it helps reduce risk of stroke and heart attack. However, new research found that both high and low levels of HDL could increase a person’s risk of premature death. Conversely, moderate HDL cholesterol levels may help in prolonging life span.
“The findings surprised us,” said Ziyad Al-Aly, MD, an assistant professor of medicine at Washington University and the study’s senior author. “Previously, it was thought that raised levels of the good cholesterol were beneficial. The relationship between increased levels of HDL cholesterol and early death is unexpected and not fully clear yet. This will require further study.”
The new research from the Washington University School of Medicine in St. Louis and Veterans Affairs St. Louis Health Care System attempts to better understand the relationship between HDL cholesterol and all-cause mortality in patients with kidney disease. The researchers established this relationship by studying the eGFR levels (kidney function). The findings are published in the Clinical Journal of the American Society of Nephrology.
Study Design and Results
The study included more than 1.7 million male US veterans with at least one eGFR test between October 2003 and September 2004. The study period was up until September 2013 or death. It was found that patients with low HDL cholesterol and low eGFR were more vulnerable to co-morbid diseases. Conversely, patients with intermediate HDL cholesterol levels had a low risk of death across all levels of eGFR.
“The findings may explain why clinical trials aimed at increasing HDL cholesterol levels failed to show improved outcomes,” Al-Aly said. There is a strong connection between HDL cholesterol levels across all kidney functions and premature death, and the study attempts to establish that connection.
“Moderation” Is the Key
For years, it was believed that HDL is “good cholesterol” and hence, having elevated levels of HDL cannot be a bad thing. However, this study debunks the myth. Having elevated or low levels are both equally harmful. The risk of premature death increases at both ends of the spectrum. Maintaining steady intermediate HDL cholesterol levels would in fact, be hugely beneficial in prolonging life span.
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
Neoadjuvant Chemotherapy Becomes Leading Initial Treatment for Advanced Epithelial Ovarian Cancer
October 22nd 2024By 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery became the most common initial treatment for patients with advanced epithelial ovarian cancer, overtaking primary cytoreductive surgery.
Read More